Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atuveciclib in advanced acute leukemia
NCT02345382Phase 1Completed
- Sponsor
- Bayer
- Start
- Feb 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of atuveciclib in acute leukemia (7 arms), sponsored by Bayer. Primary endpoints: Maximum Tolerated Dose, Maximum Total Observed Drug Concentration and 2 more. Started Feb 2015; status: completed.
02
Drugs
atuveciclib
03
Conditions
acute leukemia
Beyond the preview
Go deeper on NCT02345382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02345382.